Revenue Summary of Haemonetics Corporation

Haemonetics Corporation's latest annual revenue in 2024 was 1.3 Billion USD , up 12.01% from previous year.
Haemonetics Corporation's latest quarterly revenue in 2024 FY was 1.3 Billion USD , up 12.01% from previous quarter.
Haemonetics Corporation reported a annual revenue of 1.16 Billion USD in annual revenue 2023, up 17.67% from previous year.
Haemonetics Corporation reported a annual revenue of 993.19 Million USD in annual revenue 2022, up 14.1% from previous year.
Haemonetics Corporation reported a quarterly revenue of 343.29 Million USD for 2024 Q4, up 2.09% from previous quarter.
Haemonetics Corporation reported a quarterly revenue of 336.25 Million USD for 2024 Q3, up 5.68% from previous quarter.

Annual Revenue Chart of Haemonetics Corporation (2024 - 1991)

Historical Annual Revenue of Haemonetics Corporation (2024 - 1991)

Year	Revenue	Revenue Growth
2024	1.3 Billion USD	12.01%
2023	1.16 Billion USD	17.67%
2022	993.19 Million USD	14.1%
2021	870.46 Million USD	-11.94%
2020	988.47 Million USD	2.16%
2019	967.57 Million USD	7.04%
2018	903.92 Million USD	2.01%
2017	886.11 Million USD	-2.59%
2016	909.67 Million USD	-0.08%
2015	910.37 Million USD	-3.0%
2014	938.5 Million USD	5.22%
2013	891.99 Million USD	22.55%
2012	727.84 Million USD	7.56%
2011	676.69 Million USD	4.84%
2010	645.43 Million USD	7.95%
2009	597.87 Million USD	15.77%
2008	516.44 Million USD	14.86%
2007	449.6 Million USD	7.12%
2006	419.73 Million USD	9.42%
2005	383.59 Million USD	5.32%
2004	364.22 Million USD	8.09%
2003	336.95 Million USD	5.31%
2002	319.96 Million USD	8.88%
2001	293.86 Million USD	5.73%
2000	277.92 Million USD	-1.48%
1999	282.1 Million USD	-1.29%
1998	285.8 Million USD	-7.75%
1997	309.8 Million USD	11.36%
1996	278.2 Million USD	6.02%
1995	262.4 Million USD	5.64%
1994	248.4 Million USD	14.84%
1993	216.3 Million USD	22.62%
1992	176.4 Million USD	12.14%
1991	157.3 Million USD	0.0%

Year	Revenue	Revenue Growth
2024 Q2	318.18 Million USD	2.2%
2024 Q4	343.29 Million USD	2.09%
2024 Q3	336.25 Million USD	5.68%
2024 FY	1.3 Billion USD	12.01%
2024 Q1	311.33 Million USD	2.27%
2023 Q1	261.45 Million USD	-1.34%
2023 Q2	297.48 Million USD	13.78%
2023 Q3	305.3 Million USD	2.63%
2023 Q4	304.41 Million USD	-0.29%
2023 FY	1.16 Billion USD	17.67%
2022 Q4	265 Million USD	2.01%
2022 FY	993.19 Million USD	14.1%
2022 Q2	239.89 Million USD	4.97%
2022 Q3	259.76 Million USD	8.28%
2022 Q1	228.52 Million USD	1.55%
2021 Q3	240.37 Million USD	14.74%
2021 Q1	195.57 Million USD	-17.99%
2021 Q2	209.48 Million USD	7.11%
2021 FY	870.46 Million USD	-11.94%
2021 Q4	225.02 Million USD	-6.38%
2020 Q3	258.97 Million USD	2.54%
2020 Q2	252.56 Million USD	5.92%
2020 Q4	238.49 Million USD	-7.91%
2020 FY	988.47 Million USD	2.16%
2020 Q1	238.45 Million USD	-4.35%
2019 Q2	241.58 Million USD	5.33%
2019 Q4	249.29 Million USD	0.78%
2019 Q3	247.35 Million USD	2.39%
2019 Q1	229.34 Million USD	-1.8%
2019 FY	967.57 Million USD	7.04%
2018 Q2	225.37 Million USD	6.84%
2018 FY	903.92 Million USD	2.01%
2018 Q4	233.55 Million USD	-0.21%
2018 Q1	210.95 Million USD	-7.5%
2018 Q3	234.04 Million USD	3.85%
2017 Q1	209.95 Million USD	-13.66%
2017 FY	886.11 Million USD	-2.59%
2017 Q2	220.25 Million USD	4.9%
2017 Q4	228.06 Million USD	0.1%
2017 Q3	227.84 Million USD	3.45%
2016 Q3	233.38 Million USD	6.23%
2016 FY	909.67 Million USD	-0.08%
2016 Q1	213.41 Million USD	-5.77%
2016 Q4	243.18 Million USD	4.2%
2016 Q2	219.69 Million USD	2.94%
2015 Q1	224.48 Million USD	-6.89%
2015 Q4	226.47 Million USD	-2.31%
2015 Q3	231.82 Million USD	1.87%
2015 FY	910.37 Million USD	-3.0%
2015 Q2	227.58 Million USD	1.38%
2014 Q1	219.54 Million USD	-12.16%
2014 FY	938.5 Million USD	5.22%
2014 Q3	242.12 Million USD	2.7%
2014 Q2	235.75 Million USD	7.38%
2014 Q4	241.09 Million USD	-0.42%
2013 Q3	247.39 Million USD	13.39%
2013 Q2	218.17 Million USD	23.63%
2013 Q1	176.47 Million USD	-5.46%
2013 FY	891.99 Million USD	22.55%
2013 Q4	249.94 Million USD	1.03%
2012 Q2	179.44 Million USD	5.2%
2012 Q3	191.16 Million USD	6.53%
2012 Q4	186.67 Million USD	-2.35%
2012 Q1	170.56 Million USD	0.32%
2012 FY	727.84 Million USD	7.56%
2011 Q3	176.78 Million USD	5.97%
2011 Q1	163.03 Million USD	-3.59%
2011 Q2	166.83 Million USD	2.33%
2011 FY	676.69 Million USD	4.84%
2011 Q4	170.03 Million USD	-3.82%
2010 Q2	157.07 Million USD	1.94%
2010 Q1	154.08 Million USD	1.11%
2010 FY	645.43 Million USD	7.95%
2010 Q4	169.1 Million USD	2.38%
2010 Q3	165.16 Million USD	5.16%
2009 Q3	155.44 Million USD	6.53%
2009 Q2	145.91 Million USD	1.25%
2009 Q4	152.39 Million USD	-1.96%
2009 Q1	144.11 Million USD	3.88%
2009 FY	597.87 Million USD	15.77%
2008 FY	516.44 Million USD	14.86%
2008 Q4	138.73 Million USD	3.08%
2008 Q3	134.58 Million USD	11.06%
2008 Q1	121.93 Million USD	4.29%
2008 Q2	121.17 Million USD	-0.62%
2007 Q1	110.67 Million USD	0.25%
2007 FY	449.6 Million USD	7.12%
2007 Q4	116.91 Million USD	2.99%
2007 Q3	113.52 Million USD	4.65%
2007 Q2	108.48 Million USD	-1.98%
2006 Q2	100.48 Million USD	-2.6%
2006 Q1	103.17 Million USD	3.2%
2006 FY	419.73 Million USD	9.42%
2006 Q4	110.39 Million USD	4.46%
2006 Q3	105.67 Million USD	5.16%
2005 Q2	90.92 Million USD	-3.89%
2005 FY	383.59 Million USD	5.32%
2005 Q1	94.6 Million USD	-3.19%
2005 Q3	98.09 Million USD	7.89%
2005 Q4	99.97 Million USD	1.91%
2004 FY	364.22 Million USD	8.09%
2004 Q2	87.48 Million USD	-0.9%
2004 Q4	97.72 Million USD	7.7%
2004 Q1	88.28 Million USD	9.15%
2004 Q3	90.73 Million USD	3.71%
2003 Q4	80.88 Million USD	-7.16%
2003 FY	336.95 Million USD	5.31%
2003 Q3	87.11 Million USD	0.1%
2003 Q2	87.02 Million USD	6.21%
2003 Q1	81.93 Million USD	3.65%
2002 FY	319.96 Million USD	8.88%
2002 Q2	80.7 Million USD	6.47%
2002 Q1	75.8 Million USD	-2.44%
2002 Q3	84.41 Million USD	4.59%
2002 Q4	79.05 Million USD	-6.35%
2001 FY	293.86 Million USD	5.73%
2001 Q1	69.69 Million USD	-0.19%
2001 Q2	70.57 Million USD	1.26%
2001 Q3	75.89 Million USD	7.55%
2001 Q4	77.69 Million USD	2.37%
2000 Q3	70.8 Million USD	3.81%
2000 FY	277.92 Million USD	-1.48%
2000 Q4	69.82 Million USD	-1.38%
2000 Q1	69.1 Million USD	-7.12%
2000 Q2	68.2 Million USD	-1.3%
1999 Q1	72 Million USD	40.9%
1999 FY	282.1 Million USD	-1.29%
1999 Q4	74.4 Million USD	9.41%
1999 Q3	68 Million USD	0.29%
1999 Q2	67.8 Million USD	-5.83%
1998 Q4	51.1 Million USD	-32.59%
1998 FY	285.8 Million USD	-7.75%
1998 Q1	82.3 Million USD	-1.2%
1998 Q2	76.6 Million USD	-6.93%
1998 Q3	75.8 Million USD	-1.04%
1997 Q1	75.5 Million USD	7.24%
1997 Q4	83.3 Million USD	8.75%
1997 Q3	76.6 Million USD	2.96%
1997 Q2	74.4 Million USD	-1.46%
1997 FY	309.8 Million USD	11.36%
1996 Q2	69.1 Million USD	0.44%
1996 Q1	68.8 Million USD	0.88%
1996 Q3	69.9 Million USD	1.16%
1996 FY	278.2 Million USD	6.02%
1996 Q4	70.4 Million USD	0.72%
1995 Q4	68.2 Million USD	3.96%
1995 Q1	63.3 Million USD	-1.25%
1995 Q2	65.3 Million USD	3.16%
1995 Q3	65.6 Million USD	0.46%
1995 FY	262.4 Million USD	5.64%
1994 Q2	62.6 Million USD	7.01%
1994 Q1	58.5 Million USD	1.74%
1994 FY	248.4 Million USD	14.84%
1994 Q4	64.1 Million USD	1.42%
1994 Q3	63.2 Million USD	0.96%
1993 Q3	57.1 Million USD	7.53%
1993 Q4	57.5 Million USD	0.7%
1993 FY	216.3 Million USD	22.62%
1993 Q1	48.6 Million USD	1.25%
1993 Q2	53.1 Million USD	9.26%
1992 Q3	45 Million USD	4.17%
1992 Q4	48 Million USD	6.67%
1992 Q2	43.2 Million USD	7.73%
1992 FY	176.4 Million USD	12.14%
1992 Q1	40.1 Million USD	1.78%
1991 Q2	39.3 Million USD	0.0%
1991 Q1	39.3 Million USD	0.0%
1991 Q3	39.3 Million USD	0.0%
1991 Q4	39.4 Million USD	0.25%
1991 FY	157.3 Million USD	0.0%

Peer Revenue Comparison of Haemonetics Corporation

Name	Revenue	Revenue Difference
Alcon Inc.	10.09 Billion USD	87.029%
AptarGroup, Inc.	3.48 Billion USD	62.464%
Baxter International Inc.	14.81 Billion USD	91.163%
Becton, Dickinson and Company	20.17 Billion USD	93.512%
Bausch + Lomb Corporation	4.14 Billion USD	68.426%
Envista Holdings Corp	2.56 Billion USD	48.995%
ResMed Inc.	4.68 Billion USD	72.06%
Teleflex Incorporated	2.97 Billion USD	55.991%
Warby Parker Inc.	669.76 Million USD	-95.45%
West Pharmaceutical Services, Inc.	2.94 Billion USD	55.622%

Global Stocks Search

Haemonetics Corporation (HAE)

Revenue Summary of Haemonetics Corporation

Annual Revenue Chart of Haemonetics Corporation (2024 - 1991)

Historical Annual Revenue of Haemonetics Corporation (2024 - 1991)

Peer Revenue Comparison of Haemonetics Corporation